MyDrHank vs REMEVi
Two GLP-1 desks, one scoreboard. We put MyDrHank and REMEVi head-to-head on the published Brief Score — the same six factors, scored the same way.
REMEVi
The verdict
REMEVi takes this head-to-head.
REMEVi scores 87 to 74 on our six-factor Brief Score — REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.
That doesn't make MyDrHank a bad call — it's best for readers who already intend to prepay a year up front and want one account covering glp-1 alongside nad+, sermorelin and four other lines — and who will check the term attached to a price before treating it as a monthly bill. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| MyDrHank | REMEVi | |
|---|---|---|
| Brief Score | 74/100 (C) | 87/100 (B+) |
| Semaglutide | $259/mo (month-to-month; prepay tiers lower) | $219/mo (all doses, compounded) |
| Tirzepatide | $349/mo (month-to-month; prepay tiers lower) | $319/mo (all doses, compounded) |
| Coverage | 44 states (not KS, LA, MS, NM, ND, WV) | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
| On the tracker | Newnew to the tracker, no prior reading | Newnew to the tracker, no prior reading |
MyDrHank: First reading. The funnel advertises "from $240" tirzepatide and "from $171" semaglutide; both are twelve-month prepay rungs, and the month-to-month rates — $349 and $259 — appear on no page of it.
REMEVi: New to the tracker on 1 August 2026, and read on the provider's own site rather than taken on trust: we checked https://remevihealth.com/pricing on 2026-08-01 and this row reflects what that page says. The line we publish is $219/mo (all doses, compounded). There is no earlier reading of ours to compare it against yet.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.